Research programme - lysosomal storage diseases therapeutics - Vtesse/NCATS

Drug Profile

Research programme - lysosomal storage diseases therapeutics - Vtesse/NCATS

Alternative Names: Cyclodextrin - Vtesse/NCATS; Delta-tocopherol - Vtesse/NCATS; Niemann-Pick disease therapeutics - Vtesse/NCATS; Tocopherol derivatives - Vtesse/NCATS

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer National Center for Advancing Translational Sciences; National Institutes of Health (USA)
  • Class Cyclodextrins; Tocopherols
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Lysosomal storage diseases

Most Recent Events

  • 03 Apr 2017 Vtesse has been acquired by Sucampo Pharmaceuticals
  • 20 Jan 2015 Early research in Lysosomal storage diseases in USA (unspecified route)
  • 07 Jan 2015 Cyclodextrin, delta-tocopherol, and derivatives of tocopherol licensed to Vtesse worldwide for the treatment of Niemann-Pick disease type C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top